About Us2019-10-24T17:12:16+00:00

Cancer Ablation by Water Vapor

A Personal Journey

personal journey

The formation of Francis Medical, Inc. in 2018 is personal for Michael Hoey, the company’s co-founder and Chief Technology Officer. Michael’s medical research career began as a faculty member at the University of Minnesota where he had an academic appointment in physiology and served as an adjunct to the University of Minnesota Medical School doing research in urologic surgery. Michael also taught and did research in the University of Minnesota’s Cancer Center, the Institute of Technology and the Carlson School of Management. Michael’s research and teaching concentrated on understanding the interaction of thermal energy in tissue at the cellular and molecular levels, with a focus on prostate disorders.

From growing up on a farm in southwestern Minnesota, to teaching and researching urology disorders at the University of Minnesota, Michael spent his life solving problems. But when his father was diagnosed with prostate cancer, he was faced with a problem, yet to be solved. Michael’s father eventually passed away from the disease, and Michael left the University of Minnesota shortly thereafter to focus on the development of new thermal treatment technologies, with application throughout the body, including the prostate.
In addition to his commitment to medical research, Michael has a life-long passion for designing and building race cars. These personal and professional passions converged while Michael was testing one of his high-performance race car engines. He recognized that vaporized fuel represented a tremendous level of stored thermal energy and realized that this stored thermal energy could potentially be applied to various clinical applications when using sterile water vapor, including therapies to treat prostate and other urology conditions.

leadership team

Mike Kujak
President and CEO

Mike joins Francis Medical with more than 30 years of broad healthcare marketing and sales leadership experiences in medical devices, pharmaceutical, biotechnology, clinical research and payer economics. Prior to joining Francis Medical, Mike was the Chief Marketing Officer and Senior Vice President of International for NxThera.  Prior to NxThera he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems, which developed and commercialized medical device solutions to treat BPH, prostate cancer and stone disease. Mike received his MBA from the OPUS College of Business, University of St. Thomas in St. Paul Minnesota and a Bachelor of Science in physics and chemistry from the University of South Dakota.

Michael Hoey
Founder & Chief Technology Officer

Michael co-founded NxThera in 2008 to develop and commercialize the urology applications of the vapor platform technology that he invented. Michael has been a director and chief technology officer since NxThera’s inception. Prior to becoming an entrepreneur, Michael taught in several departments and performed research at the University of Minnesota, including the Department of Physiology, the Department of Urologic Surgery in the School of Medicine, the Institute of Technology, and the Carlson School of Management. Professor Hoey also taught in the department of Biological Sciences at Hamline University in St. Paul, Minnesota. Michael is an expert in the interaction of thermotherapy and tissue and a prolific inventor, with 72 patents granted and 94 patents pending, the majority of which are in the medical device field. Michael’s inventions include platform technologies, which are the foundation for products being sold, or in development for a variety of cardiac surgery, oncology, orthopaedics, pulmonology, general surgery, urology, gynecology, and vascular surgery applications. Michael has been a consultant to, as well as a founder/principal of, several medical products companies, which combined have raised over $250 million of capital.

Jonathan Jarow, MD
Chief Medical Officer

Dr. Jarow is a recognized leader in the field of urology. A graduate of Northwestern University School of Medicine, Dr. Jarow has held numerous prestigious positions including 14 years at John’s Hopkins School of Medicine where he was a Professor of Urology, Pathology, Radiology, and Biochemistry & Molecular Biology. He served as Clinical Investigator for multiple industry-sponsored trials and was Principal Investigator or co-Investigator on six NIH grants.  After Johns Hopkins he spent 10 years with the US Food and Drug Administration where, among other roles, he served as the Director of Office of Medical Policy (CDER) and Chief Medical Officer: Office of Device Evaluations (CDRH). He is also a renowned scholar, authoring over 100 peer-reviewed publications and while at the FDA was the Leader and Principal Organizer of multiple International FDA Workshops. In addition to his CMO position at Francis Medical, Dr. Jarow serves as CEO and Founder of FDA Solutions, LLC in Chevy Chase, Maryland.

Michael Fredrick
Director of Finance

Michael brings over 20 years of experience in the medical device industry, primarily with startup companies.  Prior to Francis Medical, he served as Vice President of Finance and Administration at NexGen Medical Systems, a Venous Thrombo-embolism technology for the treatment of Deep Vein Thrombosis.  Before NexGen Medical Systems, Michael operated his own CFO/Controller consulting company supporting companies on both long-term and short-term projects, mainly in the medical device industry, over two separate periods.  In between these two consulting phases Michael served as Vice President of Finance at BridgePoint Medical, a catheter-based technology to treat coronary chronic total occlusions. BridgePoint Medical was eventually acquired by Boston Scientific.  Michael holds a bachelor’s degree in business administration with an emphasis in accounting from the University of South Dakota and is happily married with two sons.

board of directors

André de Bruin
Chairman

Mr. de Bruin joined the NxThera board of directors in 2009 with more than 35 years of global healthcare industry experience spanning the bio-pharmaceutical, medical device and in-vitro diagnostics markets. Prior to his retirement in 2004 as executive chairman of Quidel Corporation’s board of directors, André served as the company’s chief executive officer from 1998 until 2001. He was chairman, president and chief executive officer of Somatogen, a bio-pharmaceuticals company, prior to its acquisition by Baxter. Before joining Somatogen, André was chairman, president and chief executive officer of Boehringer Mannheim Corporation, a global healthcare company subsequently acquired by Hoffman-La Roche. Past experience includes advisory services for Ferrer, Freeman and Company LLC and various boards of directors. Most recently André was a board member of Nanosphere Inc., a public company in Northbrook, IL, engaged in the field of developing and commercializing molecular diagnostics for nucleic acid detection of infectious diseases. André received a B.S. in finance, economics and business from the University of Potchefstroom in South Africa.

Jan Garfinkle
Founder & Managing Director, Arboretum Ventures

Jan Garfinkle founded Arboretum Ventures in 2002 and is a Managing Director. At Arboretum, Jan focuses on promising medical technologies that enable meaningful healthcare system savings. Jan has led more than a dozen investments and currently serves as a board director for NxThera, Cereve, NeuMoDx, and Cardiac Dimensions. Jan’s past investments include HandyLab (acquired by Becton Dickinson in 2009 for $275 million), Esperion (IPO in 2013), and CardioMEMS (acquired by St. Jude Medical in 2014 for $435 million). Prior to founding Arboretum, Jan spent 20 years in entrepreneurial healthcare companies. She was President of Strategic Marketing Consultants, advising healthcare start-ups and major medical device companies. Prior to this, Jan held key management roles for two successful medical device start-ups, Advanced Cardiovascular Systems and Devices for Vascular Intervention. Each of these companies was acquired by Eli Lilly for more than $100 million and became the foundation for Guidant Corporation. Earlier in her career, Jan was an engineer and product manager for Procter & Gamble. Jan is the past President of the Michigan Venture Capital Association, a member of the Board of Directors for the National Venture Capital Association, and a member of the Healthcare Advisory Board at the University of Michigan. Jan earned a B.S. in Bioengineering from the University of California at Berkeley and an M.B.A. from the Wharton School at the University of Pennsylvania.

David Adair MD
Director – Solas BioVentures

Dave has worked with the partners of Solas BioVentures Fund since 2004 and was a founding member of the fund in 2014. He currently focuses on investments in medical device and therapeutic companies. Board certified in Maternal-Fetal Medicine, Obstetrics and Gynecology, and Hypertension, with special expertise in Critical Care, Dave is a long-time physician, educator, administrator, innovator, and biotech/med-tech investor with nearly 20 years of experience in angel and venture investing. Dave currently serves as Professor and Vice Chairman of the Department of Obstetrics and Gynecology at the University of Tennessee College of Medicine. He is an active candidate for his MBA in Healthcare at the University of Tennessee Chattanooga. Dave received a BS in Biology from Morehead State University, where he is Hall of Fame member and earned his medical degree from the Joan C. Edwards College of Medicine at Marshall University in 1990. He completed residency at the University of Florida Health Science Center and Fellowship training at Wake Forest University.
Besides serving on the board at Francis Medical, Dave serves as a director for Arrivo Bio Ventures, Aegea Medical, Advanced Catheter Therapies, PreTel Health, Velo Bio, and Anogen Life Sciences. Dave and his colleagues have invested in many cutting edge and disruptive medical device and biotech companies, including Veran Medical Technologies (where he served previously as a board director), Addrenex (acquired by Sciele/Shionogi), Neuronex (acquired by Acorda), Velo Bio (acquired by AMAG Pharmaceuticals), Aerial Bio (acquired by Jazz Pharmaceuticals), and NxThera (acquired by Boston Scientific). Dave also founded Glenveigh Pharmaceuticals, which had products out-licensed to Protherics and acquired by Clinical Innovations.

Mike Kujak
CEO Francis Medical

Mike joins Francis Medical with more than 30 years of broad healthcare marketing and sales leadership experiences in medical devices, pharmaceutical, biotechnology, clinical research and payer economics. Prior to joining Francis Medical, Mike was the Chief Marketing Officer and Senior Vice President of International for NxThera. Prior to NxThera he was the Vice President and General Manager of the Prostate Health business unit of American Medical Systems, which developed and commercialized medical device solutions to treat BPH, prostate cancer and stone disease. Mike received his MBA from the OPUS College of Business, University of St. Thomas in St. Paul Minnesota and a Bachelor of Science in physics and chemistry from the University of South Dakota.

Michael Hoey
Founder & Chief Technology Officer

Michael co-founded NxThera in 2008 to develop and commercialize the urology applications of the vapor platform technology that he invented. Michael has been a director and chief technology officer since NxThera’s inception. Prior to becoming an entrepreneur, Michael taught in several departments and performed research at the University of Minnesota, including the Department of Physiology, the Department of Urologic Surgery in the School of Medicine, the Institute of Technology, and the Carlson School of Management. Professor Hoey also taught in the department of Biological Sciences at Hamline University in St. Paul, Minnesota. Michael is an expert in the interaction of thermotherapy and tissue and a prolific inventor, with 72 patents granted and 94 patents pending, the majority of which are in the medical device field. Michael’s inventions include platform technologies, which are the foundation for products being sold, or in development for a variety of cardiac surgery, oncology, orthopaedics, pulmonology, general surgery, urology, gynecology, and vascular surgery applications. Michael has been a consultant to, as well as a founder/principal of, several medical products companies, which combined have raised over $250 million of capital.

press releases

October 16th, 2019

Francis Medical, Inc. announced today the appointment of Dr. Jonathan Jarow as the company’s chief medical officer (CMO). Dr. Jarow will be leading Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.

Continue Reading

December 13th, 2018

Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary vapor ablation therapy to treat a variety of endourology cancers, beginning with Prostate Cancer (PCa), today announced the completion of a $18.0 million round of Series A financing.

Continue Reading

December 17th, 2018

Francis Medical, Inc. was featured in BioWorld MedTech, a leading news source of advances in medical technology.

Continue Reading

Being on the other side of the table with his father, he
realized how unattractive the options for patients with
prostate cancer were from the human side.